THE RELATIONSHIP OF ESTROGEN AND PROGESTERONE RECEPTORS TO THE PROGRESSION OF THYROID CARCINOMA AND LARYNGEAL CARCINOMA : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES
The International Journal of Medical Science and Health Research · 19.11.2026 · 49 (3) · 485-561
DOI: 10.70070/wjzgzj68 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 19.11.2026. Verfasst von Azura Fransisca Dwary und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Thyroid carcinoma shows a marked female predominance, whereas laryngeal carcinoma predominantly affects men, and both tissues express sex-steroid receptors. Whether oestrogen receptor alpha (ERα), oestrogen receptor beta (ERβ), membrane/variant oestrogen receptors (ERα36, G protein-coupled oestrogen receptor 1 [GPER1]) and progesterone receptor (PR) modify tumour progression remains controversial, and no quantitative synthesis has integrated the evidence across both malignancies. We aimed to quantify the association between ER/PR expression and markers of progression in thyroid and laryngeal carcinoma.
Methods
This review followed the PRISMA 2020 statement. PubMed/MEDLINE, Europe PMC, Semantic Scholar and ClinicalTrials.gov were searched from 1 January 2011 to 12 November 2026 and supplemented by citation searching. Randomised controlled trials, comparative studies, cohorts and case series reporting receptor expression in human thyroid or laryngeal carcinoma together with nodal metastasis, extrathyroidal extension, multifocality, tumour size, stage, vascular invasion, persistence/recurrence or survival were eligible. Risk of bias was assessed with the Quality In Prognosis Studies (QUIPS) tool and the JBI checklist for case series. Odds ratios (OR) were pooled with DerSimonian–Laird random-effects models with Hartung–Knapp–Sidik–Jonkman (HKSJ) sensitivity analyses; standardised mean differences (Hedges g) and logit-transformed proportions were pooled for continuous and prevalence data. Certainty was graded with GRADE for prognostic evidence.
Results
Of 1,989 database records and 6 records from citation searching, 34 studies (28 thyroid, 6 laryngeal; 4,478 patients) were included; no randomised trial was identified, and 24 studies contributed to meta-analyses. In thyroid carcinoma, ERα positivity was not significantly associated with lymph node metastasis (OR 1.26, 95% CI 0.96–1.65; 5 studies; 1,071 patients; I² = 0%), extrathyroidal extension (OR 1.02, 0.73–1.43) or multifocality (OR 1.18, 0.84–1.67), but was associated with larger tumour categories (OR 5.79, 3.49–9.62; 3 studies), a finding not reproduced when tumour size was analysed continuously (Hedges g 0.02, −0.33 to 0.37). ERα tended to be associated with less persistent or recurrent disease (OR 0.58, 0.29–1.18; 5 studies). In East Asian cohorts, ERα was associated with nodal metastasis (OR 1.44, 1.05–1.98). ERβ showed no consistent association with nodal metastasis (OR 0.79, 0.31–2.02; I² = 86.5%). PR positivity was associated with larger tumours (OR 2.65, 1.67–4.19) and non-significantly with persistent/recurrent disease (OR 2.94, 0.90–9.63). High ERα36/GPER1 expression was associated with nodal metastasis (OR 6.67, 1.63–27.20; 2 studies). Pooled immunopositivity was 31.0% (22.1–41.6%) for ERα, 67.5% (33.9–89.3%) for ERβ and 45.3% (31.7–59.6%) for PR in thyroid carcinoma and 37.2% (22.1–55.2%) for ERβ in laryngeal squamous cell carcinoma. Laryngeal data were limited to small series suggesting that loss of ERα66 or ERβ accompanies advanced stage. Certainty of evidence was low to very low.
Discussion
Classical nuclear ERα and PR behave as markers of tumour burden rather than robust drivers of nodal spread in thyroid carcinoma, whereas membrane-initiated oestrogen signalling through ERα36 and GPER1 shows the strongest, albeit imprecise, association with aggressive behaviour. Heterogeneous antibodies, positivity thresholds and histotypes, predominantly univariable analyses and the scarcity of laryngeal data limit causal and prognostic inference.
Conclusion
Current evidence does not support routine use of ER/PR immunohistochemistry for risk stratification of thyroid or laryngeal carcinoma. Adequately powered, prospectively designed studies using validated isoform-specific antibodies, harmonised cut-offs and multivariable time-to-event analyses are required before receptor status can inform surveillance or endocrine-targeted therapy.
Zitieren
APA
Dwary, A. F., & Mahfudhoh, M. (2026). THE RELATIONSHIP OF ESTROGEN AND PROGESTERONE RECEPTORS TO THE PROGRESSION OF THYROID CARCINOMA AND LARYNGEAL CARCINOMA : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research, 49(3), 485-561. https://doi.org/10.70070/wjzgzj68
Vancouver
Dwary AF, Mahfudhoh M. THE RELATIONSHIP OF ESTROGEN AND PROGESTERONE RECEPTORS TO THE PROGRESSION OF THYROID CARCINOMA AND LARYNGEAL CARCINOMA : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research. 2026;49(3):485-561. doi:10.70070/wjzgzj68
BibTeX
@article{Dwary2026,
author = {Dwary, Azura Fransisca and Mahfudhoh, Millah},
title = {THE RELATIONSHIP OF ESTROGEN AND PROGESTERONE RECEPTORS TO THE PROGRESSION OF THYROID CARCINOMA AND LARYNGEAL CARCINOMA : A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES},
journal = {The International Journal of Medical Science and Health Research},
year = {2026},
volume = {49},
number = {3},
pages = {485--561},
doi = {10.70070/wjzgzj68}
}
EUVIMED